Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Leukemia

Free Subscription 19.01.2026 1 Am J Hematol 13 Ann Hematol 1 Biochem Biophys Res Commun 2 Blood 1 Eur J Haematol 1 J Biol Chem 2 Leuk Lymphoma 2 Leuk Res 2 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. CASSADAY RD, DeAngelo DJ
   Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia.
   Am J Hematol. 2026 Jan 14. doi: 10.1002/ajh.70195.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. JIANG B, Li J, Liu L, Du X, et al
   Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
   Ann Hematol. 2026;105:3.
   PubMed         Abstract available
   
   
3. TARANTINI F, Contento C, Vigna E, Carluccio V, et al
   Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?
   Ann Hematol. 2026;105:1.
   PubMed         Abstract available
   
   
4. CEMAZAR L, Slajpah K, Gredelj Simec N, Podgornik H, et al
   A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL.
   Ann Hematol. 2026;105:5.
   PubMed         Abstract available
   
   
5. KARAKAS H, Tarcin G, Bayramoglu E, Turan H, et al
   Long-Term endocrine outcomes with special emphasis on the gonadal impact of acute lymphoblastic leukemia treatment in females.
   Ann Hematol. 2026;105:7.
   PubMed         Abstract available
   
   
6. JIANG Y, Luo C, Yan H, Zhu L, et al
   Does differentiation syndrome in newly diagnosed acute promyelocytic leukemia warrant systemic antifungal therapy? A real-world clinical study.
   Ann Hematol. 2026;105:8.
   PubMed        
   
   
7. ZHANG K, Ma X, Lu X, Ruan G, et al
   Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia.
   Ann Hematol. 2026;105:17.
   PubMed         Abstract available
   
   
8. PATEL SA, Khedr S, Hutchinson L, Xie Y, et al
   Portraits of clonal hematopoiesis in DNMT3A/TET2/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia.
   Ann Hematol. 2026;105:15.
   PubMed        
   
   
9. SCHENK T, Fabisch C, Ernst T, Ernst P, et al
   Ponatinib for CML patients in routine clinical practice: the PONDEROSA study.
   Ann Hematol. 2026;105:9.
   PubMed         Abstract available
   
   
10. BRUMMER C, Evert K, Keil F, Schmidt J, et al
    Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease.
    Ann Hematol. 2026;105:18.
    PubMed         Abstract available
    
    
11. ZHAO X, Ming X, Wu J, Zhu X, et al
    Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.
    Ann Hematol. 2026;105:20.
    PubMed         Abstract available
    
    
12. LI Y, Shang Y, Liu K, Liu Y, et al
    Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study.
    Ann Hematol. 2026;105:23.
    PubMed         Abstract available
    
    
13. ZHANG ZX, Zhang L, Lu AD, Zhang LP, et al
    Paediatric blastic plasmacytoid dendritic cell neoplasm: a single-centre case series of 18 children and review of the literature.
    Ann Hematol. 2026;105:25.
    PubMed         Abstract available
    
    
14. WU L, Liu P, Jiang B, Zhang X, et al
    Lycorine inhibits the proliferation of acute myeloid leukemia cells by upregulating the expression of THBS1.
    Ann Hematol. 2026;105:24.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

15. WANG B, Wang HL, Ye YF, Song JZ, et al
    Ferroptosis regulation and acute leukemia: Mechanisms and therapeutic perspectives.
    Biochem Biophys Res Commun. 2026;800:153284.
    PubMed         Abstract available
    
    

    
    Blood

16. POPESCU B, Jones MF, Piao M, Tran E, et al
    Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
    Blood. 2026;147:276-289.
    PubMed         Abstract available
    
    
17. AL-SAWAF O, Locher BN, Christen F, Hablesreiter R, et al
    The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.
    Blood. 2025 Dec 23:blood.2025029905. doi: 10.1182/blood.2025029905.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

18. SEKAR AJ, Sakthivel S, Valsala Gopalakrishnan A, Vashishth R, et al
    An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies.
    Eur J Haematol. 2026 Jan 13. doi: 10.1111/ejh.70110.
    PubMed         Abstract available
    
    

    
    J Biol Chem

19. YADAV A, Richartz N, Bhagwat S, Burman MM, et al
    Starvation of leukemic cells enhances DNA damage-induced apoptosis in vitro via ROS/p38 MAPK and prevents leukemia progression in fasting xenograft mice.
    J Biol Chem. 2026 Jan 12:111143. doi: 10.1016/j.jbc.2026.111143.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

20. BLOMBERY P, McKeague S, Hartog B, Nguyen T, et al
    KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia.
    Leuk Lymphoma. 2026 Jan 13:1-3. doi: 10.1080/10428194.2026.2615055.
    PubMed        
    
    
21. PULLANUR KARUMAMPURATH A, Errington A, Norman P, Hayes L, et al
    Patterns and trends in the incidence of leukemia in children and young adults in Northern England by age, sex, socioeconomic and urban-rural status.
    Leuk Lymphoma. 2026 Jan 13:1-7. doi: 10.1080/10428194.2025.2612236.
    PubMed         Abstract available
    
    

    
    Leuk Res

22. ALHURAIJI A, Alhejazi A, Bagal B, Lin CY, et al
    Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study.
    Leuk Res. 2026;160:108152.
    PubMed         Abstract available
    
    
23. TSUKAHARA F, Kaji K, Maru Y
    Identification and characterization of peptidyl-prolyl isomerase Pin1 as a new regulatory component of BCR::ABL1 degradation.
    Leuk Res. 2026;160:108146.
    PubMed         Abstract available
    
    

    
    Leukemia

24. HERNANDEZ-SANCHEZ A, Villaverde Ramiro A, Strang E, Turki AT, et al
    Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.
    Leukemia. 2026 Jan 14. doi: 10.1038/s41375-025-02851.
    PubMed         Abstract available
    
    
25. BURCHERT A, Nicolini FE, le Coutre P, Saussele S, et al
    Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
    Leukemia. 2026 Jan 12. doi: 10.1038/s41375-025-02859.
    PubMed         Abstract available
    
    

    
    PLoS One

26. LIANG Q, Li B, Li Y, Ma L, et al
    DC-STAMP activates the PI3K/AKT/mTOR signaling pathway to regulate PANoptosis in acute myeloid leukemia.
    PLoS One. 2026;21:e0339670.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.